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• The fine line between success and failure in scleroderma lung fibrosis trials 
 
Scleroderma (systemic sclerosis; SSc) is a complex multisystem disease with high morbidity and 
mortality. Pulmonary complications are a major cause of death in SSc; however, there are few 
effective treatments of lung fibrosis (interstitial lung disease; ILD). The evidence base for the current 
approach of using broad-spectrum immunosuppression with mycophenolate mofetil or 
cyclophosphamide in SSc-ILD has been supported by three prospective randomized trials, but in 
general these trials are difficult to design and execute. This is primarily due to SSc-ILD being a rare 
disease with a relatively slow rate of progression compared with idiopathic pulmonary fibrosis (IPF). 
This slower progression is reassuring for patients, but makes it more challenging to adequately 
power clinical trials. However, despite these challenges, it is important to undertake studies given 
the substantial impact of pulmonary fibrosis on morbidity and mortality in SSc, and a number of 
trials are underway.  
 
Current trials need to proceed in the landscape of previous studies and should incorporate lessons 
learned from earlier success or failure. Prospective randomized clinical trials of patients with SSc-ILD 
have been challenging, but even studies that are unequivocally negative, such as BUILD-2 (1), have 
provided valuable prospective data on the natural history of SSc-ILD and the measurement 
variability of common clinical trial endpoints. The most recent SSc-ILD trial is SLS2 that compared 
oral cyclophosphamide to mycophenolate mofetil in 126 patients with SSc-ILD (2). This study, 
together with SLS1 that compared oral cyclophosphamide to placebo (3), provides a large and well-
characterized cohort that can be used to assess change in lung function parameters over 12 and 24 
months. These two studies have similar study populations, endpoints, and follow up durations, 
providing a valuable opportunity to integrate patient-level data and perform a combined analysis to 
address challenging questions. 
 
One of the potential opportunities permitted by such cohorts is estimation of the minimum clinically 
important difference (MCID), a goal that is particularly relevant in studies that demonstrated an 
improvement in clinically important outcomes. The MCID is defined as the minimum change in a 
measurement that can be reliably detected by a patient (4). The MCID term was first introduced into 
the pulmonary medicine lexicon in 1989 when applied to questionnaires measuring the impact of 
chronic respiratory disease and congestive heart failure (4). Since this first report, many studies have 
used both distribution- or anchor-based approaches, and ideally both, to determine MCIDs for 
multiple outcomes in a variety of pulmonary diseases (5). The distribution-based approach relies on 
the frequency distribution of a variable and provides an estimation of the magnitude of change that 
is likely to be statistically, and possibly clinically, significant. The anchor-based approach requires 
measurement of a second variable that typically has an established MCID and is correlated with the 
outcome of interest. This association is used to determine the magnitude of change in the outcome 
of interest that corresponds to the MCID of the second variable. The anchor-based approach can 
thus link a less important outcome to an important clinical outcome to help explain the clinical 
implications of change in this less important outcome, an advantage that is particularly helpful for 
endpoints like the FVC that have limited importance to patients in isolation. The SLS 1 and 2 trials 
provide an excellent opportunity to determine an anchor-based MCID for FVC because the change in 
pulmonary function can be anchored to other clinically relevant variables that were recorded in 
these studies. In this way, Kafaja and colleagues used robust data from two important trials to 
determine a group level MCID of approximately 3-5% for FVC in SSc-ILD (6). 
 
One recurring challenge in placebo-controlled SSc-ILD studies has been that the average benefit of 
therapy on FVC is small, despite being statistically significant (3, 7). At first glance, this FVC MCID of 
3-5% is underwhelming as it is less than usual measurement error and this change would not 
generally be regarded as clinically meaningful.(8, 9) However, it is often more helpful to consider the 
MCID as a threshold that can yield a number needed to treat. This type of analysis will be important 
for ongoing similar clinical trials in diseases like SSc-ILD that can have a widely variable response to 
therapy. The small MCID in SSc-ILD and relatively slow progression will also make add-on studies 
such as RECITAL particularly challenging to power (10), but it is notable that one of the most 
ambitious SSc-ILD studies to date, targeting 520 patients randomised to nintedanib or placebo, and 
stratified for background immunosuppressive therapy, has recently reached full recruitment (11). 
 
An important caveat is that these findings do not apply to an individual patient in clinical practice, as 
these are group-level effects derived from large trial populations evaluated as a whole. Individual 
patient analyses, such as that of Goh et al 2017 (12), are more likely to be useful when evaluating 
potential treatment effects within a single patient. Another important caveat is that the FVC is not 
only representing the impact of immunosuppressive therapy on ILD severity, and that there are 
additional manifestations of SSc-ILD that are in part captured by FVC (e.g., muscle weakness, pleural 
disease). The immunosuppressive therapies in the SLS-1 and -2 studies may impact both ILD and 
non-ILD determinants of FVC, suggesting that the MCID now derived from Kafaja et al is not only 
reflecting the impact of therapy on ILD severity, and is instead measuring the total impact of these 
therapies on lung function that may occur through multiple mechanisms. These additional 
determinants of FVC in SSc-ILD are unique compared to many other ILDs that are isolated 
parenchymal lung disorders, and may explain some of the differences in the MCID of FVC in SSc-ILD 
compared to other chronic lung diseases (13, 14). 
 
The multiple determinants of FVC in SSc-ILD are in some ways desirable as FVC is thus a more 
complete measure of disease severity that provides a better estimate of a patient’s overall 
wellbeing. Conversely, there are some situations in which one desires a more pure measure of ILD 
severity. Lung function measurements, including FVC and especially DLCO, are likely imperfect 
surrogates for this purpose given the likely high noise to signal ratio. This limitation has led to recent 
efforts to identify other potential endpoints for fibrotic ILD, including both visual and quantitative 
assessment of ILD severity on computed tomography in SSc and other fibrotic ILDs (15, 16). 
Quantitative imaging is a powerful new tool that is quickly becoming a standard key endpoint in 
clinical trials for multiple fibrotic ILDs, and this may be a highly advantageous efficacy measure in 
early-phase proof-of-concept clinical trials. Identifying the MCID for FVC and other endpoints is 
critical to support use of these novel endpoints by providing clinical context to outcomes that are 
otherwise of relatively little direct importance to patients. 
 
In conclusion, we can now start to draw on lessons of recent studies to improve understanding of 
treatment effects in future trials. This is valuable because patients, regulators and payers will want 
to know whether new and potentially expensive therapies offer clinical benefit, an acceptable risk: 
benefit profile, and value for money. This paper reminds us that clinical trials can generate much 
additional information beyond the primary analysis and that such data should be fully available and 
utilized from both commercial and academic studies. However, it is also important that conclusions 
based upon group level data and estimates of MCID are applied with caution to individual patients 
when making treatment or funding decisions, and to ensure that trial-derived metrics do not 
become a barrier to access when striving for cost-effective and evidence-based treatment of 
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